Aristolochic acid C

CAS No. 4849-90-5

Aristolochic acid C( 10-Hydroxy-6-nitrophenanthro[3,4-d]-1,3-dioxole-5-carboxylic acid )

Catalog No. M29048 CAS No. 4849-90-5

Aristolochic acid C is a derivative of Aristolochic acid which is a phospholipase A2 inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 102 In Stock
5MG 107 In Stock
10MG 160 In Stock
25MG 269 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Aristolochic acid C
  • Note
    Research use only, not for human use.
  • Brief Description
    Aristolochic acid C is a derivative of Aristolochic acid which is a phospholipase A2 inhibitor.
  • Description
    Aristolochic acid C is a derivative of Aristolochic acid which is a phospholipase A2 inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    10-Hydroxy-6-nitrophenanthro[3,4-d]-1,3-dioxole-5-carboxylic acid
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    4849-90-5
  • Formula Weight
    327.248
  • Molecular Formula
    C16H9NO7
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (381.97 mM)
  • SMILES
    OC(=O)c1cc2OCOc2c2c3cc(O)ccc3cc([N+]([O-])=O)c12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • AER-271

    AER-271 (AER271) is a selective, small molecule inhibitor of aquaporin-4 (AQP4), the prodrug of AER-270 with enhanced solubility.

  • Maculosidin

    Maculosidine affect the PS I electron acceptors on leaf discs, it can inhibit ATP synthesis, basal, phosphorylating and uncoupled electron transport acting as Hill reaction inhibitors on spinach chloroplasts.

  • JNJ-26990990

    JNJ-26990990 is a broad-spectrum anticonvulsant drug as a second-generation followup to the marketed drug topiramate.